Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy

Rheumatology (Oxford). 2013 Jan;52(1):218-20. doi: 10.1093/rheumatology/kes351.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnosis*
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology
  • Diphosphonates / adverse effects*
  • Diphosphonates / therapeutic use
  • Female
  • Humans
  • Infliximab
  • Osteoporosis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Diphosphonates
  • Infliximab